Article 26 Apr 2024 Federal Circuit Dismisses Appeals In Regeneron v. Mylan (Aflibercept) BPCIA Litigation United States Healthcare
Article 05 Sep 2022 Outlook Therapeutics Re-Submits Its Ophthalmic Bevacizumab BLA United States Healthcare
Article 08 Jul 2022 Fintiv 2.0: USPTO Director Issues Guidance Softening Risk Of Discretionary Denial United States IP
Article 19 May 2022 Alvotech Announces Positive Results From A Pharmacokinetic Similarity Study For Ustekinumab Biosimilar United States Healthcare
Article 15 Apr 2022 FDA Accepts Regeneron And Sanofi's DUPIXENT (Dupilumab) SBLA For Priority Review United States Healthcare